HOME >> MEDICINE >> NEWS
Takeda responds to the FDA advisory committee recommendation

Deerfield, IL, July 30, 2007 Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS ; (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

The breadth and depth of ACTOS data encompassing more than 16,000 patients over the past 10 yearsis consistent: Short- and long-term studies, both prospective and observational, studies in both humans and animals, all have shown no evidence that ACTOS is associated with an increased risk of heart attack or stroke, said Mehmood Khan, M.D., TGRD president. Critical in this body of data is the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study, since the only scientific way to determine a medications safety is a prospective, long-term trial.

About the PROactive Study

PROactive was a prospective, randomized, placebo-controlled outcomes trial. The PROactive study included 5,238 patients with type 2 diabetes and a history of macrovascular disease, who were force titrated up to 45 mg daily of either ACTOS or placebo. In this study, there was no difference in the number of macrovascular events between standard of care and ACTOS, and standard of care alone. Although there was no statistically significant difference between ACTOS and standard of care for the primary endpoint, there was no increase in mortality or total macrovascular events with ACTOS.

The ACTOS Prescribing Information was recently revised by the FDA to include this reassuring cardiovascular safety data. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Although drugs may be in the same class, they also can have different clinical effects due to differences
'"/>

Contact: Cristina Sotolongo
Cristina.Sotolongo@ketchum.com
646-935-4021
Ketchum
30-Jul-2007


Page: 1 2

Related medicine news :

1. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
2. Takeda submits new drug application for combination type 2 diabetes medication
3. Stubborn ulcerative colitis responds to arthritis drug, review finds
4. American Egg Board responds to proposed USDA rule to revise WIC food package
5. Bradley Hospital responds to FDA report on ADHD drugs
6. Life-threatening lupus responds to stem cell transplant therapy
7. Pain research using electronic diaries helps identify who responds to placebo effect
8. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
9. ARRS president responds to NAS report on ionizing radiation
10. Medical, IT, engineering experts form advisory panel for electronic health record safety
11. National Academies advisory: Native African vegetables

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2018)... ... December 06, 2018 , ... ... tropical disease schistosomiasis significantly faster than the drug most commonly used against the ... Democratic Republic of Congo. The study’s authors, including a professor and two research ...
(Date:12/6/2018)... ... 06, 2018 , ... The University of Utah’s Gymnastics team is ... Indigo-Clean continuous environmental disinfection. The lights are installed in the team’s athletic ... programs across the nation by providing this new, proven bacteria fighting technology as another ...
(Date:12/5/2018)... HOUSTON (PRWEB) , ... December 05, 2018 , ... ... to be one of the first plastic surgery practices in Houston to offer ... career to bringing his patients an innovative range of surgical and noninvasive techniques ...
(Date:12/5/2018)... SANTA BARBARA, Calif. (PRWEB) , ... December 05, 2018 , ... ... gearing up for its annual global celebration “A Toast Heard ‘Round the World” on ... Travis-Teague invites members of the school’s global community (alumni, students, faculty members, staff, families, ...
(Date:12/5/2018)... ... 2018 , ... Since PermaLip™ implants are solid, patients do not ... naked eye, ensuring a natural look. “I always double and triple check implant placement ... implant visibility,” says Dr. Jessica Kulak, double board certified facial plastic surgeon at The ...
Breaking Medicine News(10 mins):
(Date:12/6/2018)... ... December 06, 2018 , ... Today, the Alternative ... for the millions of Americans and people worldwide who suffer first-hand with drug ... renowned Alternative to Meds Center utilizes the tenets of neurochemistry in assessing each ...
(Date:12/5/2018)... , ... December 05, 2018 , ... Trivellini Tech announces ... Long Hair, based on a version previously known as Mamba Nano, Trivellini Long Hair ... Dr. Trivellini, this version of “Trivellini system has the same capabilities as the last ...
(Date:12/5/2018)... ... December 04, 2018 , ... Florida Hospital West ... and quality. Today, the prestigious Leapfrog Group, a national nonprofit health care ratings ... Hospital Heartland Medical Center Sebring, Florida Hospital Wesley Chapel and Florida Hospital Zephyrhills ...
Breaking Medicine Technology:
Cached News: